JP2022504392A5 - - Google Patents

Info

Publication number
JP2022504392A5
JP2022504392A5 JP2021518891A JP2021518891A JP2022504392A5 JP 2022504392 A5 JP2022504392 A5 JP 2022504392A5 JP 2021518891 A JP2021518891 A JP 2021518891A JP 2021518891 A JP2021518891 A JP 2021518891A JP 2022504392 A5 JP2022504392 A5 JP 2022504392A5
Authority
JP
Japan
Prior art keywords
antibody fragment
human
domain
met antibody
amino acid
Prior art date
Application number
JP2021518891A
Other languages
English (en)
Japanese (ja)
Other versions
JPWO2020074459A5 (https=
JP7371093B2 (ja
JP2022504392A (ja
Filing date
Publication date
Priority claimed from IT102018000009282A external-priority patent/IT201800009282A1/it
Application filed filed Critical
Publication of JP2022504392A publication Critical patent/JP2022504392A/ja
Publication of JPWO2020074459A5 publication Critical patent/JPWO2020074459A5/ja
Publication of JP2022504392A5 publication Critical patent/JP2022504392A5/ja
Application granted granted Critical
Publication of JP7371093B2 publication Critical patent/JP7371093B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2021518891A 2018-10-09 2019-10-07 腫瘍および／または転移の治療のための抗－ｍｅｔ ｆａｂ－ｆｃ Active JP7371093B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IT102018000009282A IT201800009282A1 (it) 2018-10-09 2018-10-09 Nuovo agente terapeutico per il trattamento di un tumore e/o metastasi
IT102018000009282 2018-10-09
PCT/EP2019/077116 WO2020074459A1 (en) 2018-10-09 2019-10-07 Anti-met fab-fc for the treatment of a tumor and/or metastasis

Publications (4)

Publication Number Publication Date
JP2022504392A JP2022504392A (ja) 2022-01-13
JPWO2020074459A5 JPWO2020074459A5 (https=) 2022-05-12
JP2022504392A5 true JP2022504392A5 (https=) 2022-05-12
JP7371093B2 JP7371093B2 (ja) 2023-10-30

Family

ID=65010823

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021518891A Active JP7371093B2 (ja) 2018-10-09 2019-10-07 腫瘍および／または転移の治療のための抗－ｍｅｔ ｆａｂ－ｆｃ

Country Status (23)

Country Link
US (2) US12209129B2 (https=)
EP (2) EP3864050B1 (https=)
JP (1) JP7371093B2 (https=)
KR (2) KR20250078600A (https=)
CN (2) CN119587692A (https=)
AU (2) AU2019358417B2 (https=)
CA (1) CA3115582A1 (https=)
CY (1) CY1125831T1 (https=)
DK (1) DK3864050T5 (https=)
ES (1) ES2938714T3 (https=)
FI (1) FI3864050T3 (https=)
HR (1) HRP20230154T1 (https=)
HU (1) HUE060843T2 (https=)
IL (1) IL282033B2 (https=)
IT (1) IT201800009282A1 (https=)
LT (1) LT3864050T (https=)
PL (1) PL3864050T3 (https=)
PT (1) PT3864050T (https=)
RS (1) RS63960B1 (https=)
SG (1) SG11202103575RA (https=)
SI (1) SI3864050T1 (https=)
SM (1) SMT202300053T1 (https=)
WO (1) WO2020074459A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20260019463A (ko) 2023-06-01 2026-02-10 피에르 파브르 메디카먼트 종양 및 전이의 치료를 위한 침묵화된 항체 기반의 항-met 구조물

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100956913B1 (ko) * 2003-12-19 2010-05-11 제넨테크, 인크. 치료제로서 유용한 일가 항체 단편
CA2638889C (en) 2006-02-06 2015-06-02 Metheresis Translational Research S.A. Anti-met monoclonal antibody, fragments and vectors thereof, for the treatment of tumors and corresponding products
ES2547248T3 (es) * 2006-04-28 2015-10-02 Delenex Therapeutics Ag Anticuerpos que se unen al dominio extracelular del receptor Tirosina cinasa ALK
NZ591087A (en) * 2008-10-01 2012-08-31 Micromet Ag Cross-species-specific pscaxcd3, cd19xcd3, c-metxcd3, endosialinxcd3, epcamxc d3, igf-1rxcd3 or fapalpha xcd3 bispecific single chain antibody
EP2376109B1 (en) * 2008-12-19 2019-01-23 MacroGenics, Inc. Covalent diabodies and uses thereof
MX2011010265A (es) * 2009-04-01 2011-10-11 Genentech Inc Anticuerpos anti-fcrh5 e inmunoconjugados y metodos de uso.
DK2500036T3 (da) * 2011-03-18 2014-08-04 Metheresis Translational Res Sa MET-hæmmere til øgning af virkningen af radioterapi
KR20140033029A (ko) * 2011-04-01 2014-03-17 메모리얼 슬로안-케터링 캔서 센터 에이치엘에이 에이2에 의해 제공된 더블유티1 펩타이드에 특이적인 티 세포 수용체 유사 항체
EP2748197A2 (en) * 2011-08-26 2014-07-02 Merrimack Pharmaceuticals, Inc. Tandem fc bispecific antibodies
EP2782932A1 (en) * 2011-11-21 2014-10-01 F.Hoffmann-La Roche Ag Purification of anti-c-met antibodies
ITTO20130012A1 (it) * 2013-01-09 2014-07-10 Metheresis Translational Res S A Nuovi frammenti anticorpali, relative composizioni ed usi
GB201403875D0 (en) * 2014-03-05 2014-04-16 Cantargia Ab Novel antibodies and uses thereof
MX2019008538A (es) * 2017-01-20 2019-11-05 Juno Therapeutics Gmbh Conjugados de superficie celular y composiciones y métodos celulares relacionados.

Similar Documents

Publication Publication Date Title
CN115057936B (zh) 异源二聚体多特异性抗体形式
NZ717476A (en) Anti-garp protein and uses thereof
EA032681B1 (ru) ГЕТЕРОДИМЕР Fc ИММУНОГЛОБУЛИНА, СОДЕРЖАЩИЙ ВАРИАНТ ДОМЕНА CH3 ДЛЯ ОБРАЗОВАНИЯ АНТИТЕЛА ИЛИ ГИБРИДНОГО БЕЛКА С ГЕТЕРОМЕРНЫМ Fc С ВЫСОКОЙ ЭФФЕКТИВНОСТЬЮ, СПОСОБ ДЛЯ ЕГО ПОЛУЧЕНИЯ И ИСПОЛЬЗОВАНИЯ
JP2020536512A (ja) タンパク性ヘテロ二量体及びその使用
JP2023514371A (ja) 操作された抗ｈｅｒ２二重特異性タンパク質
JP7792044B2 (ja) ヒト化抗ｉｌ－１ｒ３抗体及び使用方法
JP7657591B2 (ja) 二重特異性抗原結合コンストラクト
WO2020015687A1 (zh) 抗her3人源化单克隆抗体及其制剂
CN117120478A (zh) 一种抗原结合分子
WO2024046301A1 (zh) 包含taci多肽的融合蛋白及其用途
WO2023174238A9 (zh) 特异性结合gprc5d和cd3的抗原结合分子及其医药用途
JP2021518170A5 (https=)
JP2022504392A5 (https=)
WO2020192648A1 (en) Proteinaceous heterodimer and use thereof
EP4559932A1 (en) Multispecific antibody and use thereof
FI3864050T3 (fi) Anti-met-fab-fc kasvaimen ja/tai metastaasin hoitamiseksi
JPWO2020074459A5 (https=)
JPWO2022166728A5 (https=)
US20260109781A1 (en) Anti-her2 antibodies and methods of use thereof
JP2024534824A (ja) 操作された抗ｈｅｒ２二重特異性タンパク質
HK40110414A (zh) 抗her2抗体及其使用方法
HK40084724A (en) Engineered anti-her2 bispecific proteins
WO2024188319A1 (zh) 抗muc17、cd3和cd28三特异性抗体
WO2024131849A1 (zh) Cd38单克隆抗体及其应用
WO2025140701A1 (zh) 抗egfr单抗、其双特异性抗体、药物组合物和用途